Adalimumab also has a number of serious safety concerns, potentially fatal, typical of the TNF class, and it too black-box warning on its FDA label.
Adalimumab also has a number of serious safety concerns, potentially fatal of the TNF class, and it too black-box warning on its FDA label. This is typical.